` OPT (Opthea Ltd) vs S&P/ASX 300 Comparison - Alpha Spread

OPT
vs
S
S&P/ASX 300

Over the past 12 months, OPT has underperformed S&P/ASX 300, delivering a return of -8% compared to the S&P/ASX 300's +4% growth.

Stocks Performance
OPT vs S&P/ASX 300

Loading
OPT
S&P/ASX 300
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
OPT vs S&P/ASX 300

Loading
OPT
S&P/ASX 300
Difference
www.alphaspread.com

Performance By Year
OPT vs S&P/ASX 300

Loading
OPT
S&P/ASX 300
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Opthea Ltd vs Peers

S&P/ASX 300
OPT
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Opthea Ltd
Glance View

Market Cap
820.8m AUD
Industry
Biotechnology

Opthea Ltd. is a clinical stage biopharmaceutical company that engages in the development of biological therapeutics for the treatment of progressive retinal diseases. The company is headquartered in Melbourne, Victoria. The firm is engaged in developing and commercializing therapies primarily for eye diseases. The firm's lead product candidate OPT-302, is a soluble form of vascular endothelial growth factors-3 (VEGFR 3) in clinical development as a therapy for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The firm's technology platform focuses on vascular endothelial growth factors, such as VEGF C, VEGF D and VEGF Receptor 3 for the treatment of diseases associated with blood and lymphatic vessel growth (angiogenesis and lymphangiogenesis), as well as vascular leakage. The company has also conducted various activities to support its clinical development programs in wet AMD and DME, including clinical data analysis and manufacturing of OPT-302 for use in Phase III clinical trials.

OPT Intrinsic Value
0.23 AUD
Overvaluation 61%
Intrinsic Value
Price
Back to Top